EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that lead compounds from each of two different types of drugs being developed as potential treatment for specific types of brain cancers have activity against human pancreatic cancers in a mouse model.
Dr. John S. Kovach, President and CEO of Lixte, said, "Lixte previously reported that lead compounds from each of two different classes of pharmacologic agents have significant inhibitory activity against several types of human cancers in the test tube and against brain cancers in animal models. We have now found that two different lead compounds also have statistically significant activity against human pancreatic cancer cells growing in mice. These are early studies and there is no evidence that these drugs are able to eliminate pancreatic cancers but rather slow their growth. We are encouraged, however, that two classes of our drugs have activity against this devastating cancer in addition to glioblastoma multiforme, the most common and most malignant form of brain cancer."
About Lixte Biotechnology Holdings, Inc.:
Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.
This announcement contains certain forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, and Section 21E
of the Securities Exchange Act of 1934. For example, statements regarding
the Company's financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions about
future product demand, supply, manufacturing, costs, marketing and pricing
factors are all forward-looking statements. These statements are generally
accompanied by words such as "intend," anticipate," "believe," "estimate,"
"potential(ly)," "continue," "forecast," "predict," "plan," "may," "will,"
"could," "would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions and
expectations reflected in such forward-looking statements are reasonable,
based on information available to it on the date hereof, but the Company
cannot provide assurances that these assumptions and expectations will
prove to have been correct or that the Company will take any action that
the Company may presently be planning. However, these forward-looking
statements are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially from
those expected or anticipated in the forward-looking statements. Factors
that could cause or contribute to such differences include, but are not
limited to, regulatory policies, available cash, research results,
competition from other similar businesses, and market and general economic
factors. This discussion should be read in conjunction with the condensed
consolidated financial statements and notes thereto included on Forms 10K
Please see our Website:
For Investor Information, please contact:
Mirador Consulting, Inc. 561-989-3600
|SOURCE Lixte Biotechnology Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved